ImmoGnost GmbH is the future-oriented joint venture of the companies Fassisi GmbH (development and production of on-site rapid test systems for the veterinary sector) and miprolab GmbH
(microbiological diagnostics and detection of biological warfare agents, bacteria, viruses, toxins and metabolites) and specialises in lateral flow analysis (LFA).
The two parent companies are based in Göttingen and have more than 10 years of experience in the development, production and use of rapid test systems for veterinary and human applications.
ImmoGnost's CE-certified SARS-CoV-2 (COVID-19) rapid test features a high sensitivity of 96.19% and specificity of 99.04% and is the first COVID-19 antigen rapid test to be produced entirely in Germany. This is true not only of the production location, but also of all critical raw materials used.
The ImmoGnost SARS-CoV-2 (COVID-19) Rapid Test is a point-of-care test that must be performed by medically trained personnel. It does not, however, require additional staff to determine the results, nor does it require a corresponding laboratory.